SYMPOSIUM: Redefining SFA treatment in a drug-eluting world supported with an educational grant from Boston Scientific

Prof. I. Baumgartner
Head Clinical & Interventional Angiology
University Hospital Bern
Disclosure

Speaker name:

............Baumgartner.................................................................

I have the following potential conflicts of interest to report:

☐ Consulting
☐ Employment in industry
☐ Stockholder of a healthcare company
☐ Owner of a healthcare company
☐ X Other(s)

   Educational grand Boston Scientific

☐ I do not have any potential conflict of interest
POBA

Immediately post-procedure

Stents

Artery wall contracts
Elastic recoil
External elastic membrane shrinks
Negative arterial remodeling

Drugs

Intimal layer increases in thickness
Neointimal hyperplasia
DCB vs DES
Redefining SFA treatment in a drug-eluting world

DCB: prevent neointimal proliferation (*over time*)
- to deliver drugs without stent scaffold
- nothing left behind, no/shorter anti-platelet therapy (DAPT)
- *CONS* lesion length & calcification, no class effect

SUPPLEMENTARY TO OPTIMAL POBA WITHOUT CALCIFICATION

DES: prevent technical failure (*acute*) & neointimal proliferation
- *site-specific, controlled release while maintaining scaffolding properties of BMS*
- *CONS* chronic inflammation, stimulus for hyperplasia & ISR, re-do poor outcome, DAPT

COMPLEMENTARY TO SUBOPTIMAL POBA
Remark on Trial Design

**Zilver PTX Randomized**

- **Zilver PTX RCT**
  - Zilver PTX (Drug Eluting Stent)
  - **PTA (Bare Balloon)**
    - **Successful (Optimal PTA)**
      - 2-year Patency: 53%
    - **Failed (Suboptimal PTA)**
      - Zilver PTX (Drug Eluting Stent)
      - Bare Metal Stent
      - 2-year Patency: 83.4%
      - 2-year Patency: 64%

**Included in ZPTX Trial**

**DCB Trial Designs**

- **Pre-dilation (Std. PTA)**
  - **Failed (Suboptimal PTA)**
  - **Successful (Optimal PTA)**
    - Drug Coated Balloon
      - 2-year Patency: 78.9%
    - Bare Balloon (Std. PTA)
      - 2-year Patency: 50.1%

**Excluded in DCB Trials**
• Drug coated balloons – for all or some?
• Eluvia drug eluting stent: A platform for success?
• *Live case transmission from Leipzig University Hospital Leipzig - Live case center*
• Getting to answers with clinical trials: being bold
• Why you should care about health economics in PAD: Funding meaningful innovation
SYMPOSIUM:
Redefining SFA treatment in a drug-eluting world
supported with an educational grant from Boston Scientific

Prof. I. Baumgartner
Head Clinical & Interventional Angiology
University Hospital Bern